Moreover, AML cell clones harboring mutant NRAS arise in some patients relapsing on targeted therapies, particularly FLT3 inhibition (crenolanib56 and gilteritinib57) and BCL2 inhibition in some cases (venetoclax58,59). The gene discussed is NRAS; the disease is acute myeloid leukemia.